GASTROESOPHAGEAL JUNCTION CARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION CARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to slow stomach cancer progression
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…
Matched conditions: GASTROESOPHAGEAL JUNCTION CARCINOMA
Phase: PHASE2 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug INCB123667 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…
Matched conditions: GASTROESOPHAGEAL JUNCTION CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…
Matched conditions: GASTROESOPHAGEAL JUNCTION CARCINOMA
Phase: PHASE1 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Common antifungal drug shows promise against esophageal cancer
Disease control Recruiting nowThis phase II trial tests whether adding itraconazole, a common antifungal medication, to standard chemoradiation can improve outcomes for people with resectable esophageal cancer. About 78 participants will receive itraconazole before and after standard treatment, then undergo s…
Matched conditions: GASTROESOPHAGEAL JUNCTION CARCINOMA
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer care at home: a Game-Changer for patients?
Symptom relief Recruiting nowThis study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…
Matched conditions: GASTROESOPHAGEAL JUNCTION CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New algorithm aims to keep chemo on track for stomach and colon cancers
Symptom relief Recruiting nowThis study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…
Matched conditions: GASTROESOPHAGEAL JUNCTION CARCINOMA
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC